BeOne Medicines Expands Beijing R&D Center to Accelerate Oncology Drug Development
Key Insights
BeOne Medicines (search) inaugurated its expanded R&D innovation center in Beijing's Changping district, increasing the facility to 47,674 square meters and accommodating over 1,300 staff members.
The expanded center enhances capabilities in immuno-oncology (search), inflammation (search), and cutting-edge platforms including targeted protein degradation (search) and antibody-drug conjugates (search).
BeOne's global R&D network includes over 40 products in clinical or commercial stages, with 13 new molecular entities advanced in 2024 alone.
Global oncology (search) company BeOne Medicines (search) inaugurated its expanded research and development innovation center in Beijing's Changping district on Tuesday, marking a significant step in strengthening its global research capabilities. The facility expansion represents a major investment in China's growing biotechnology sector and positions BeOne to accelerate its oncology drug development pipeline.
Facility Expansion Details
Located in the Zhongguancun Life Science Park (search), the new facility expands the center's total floor area to 47,674 square meters, accommodating over 1,300 staff members. The expanded center enhances capabilities in immuno-oncology (search), inflammation (search), and cutting-edge platforms like targeted protein degradation (search) and antibody-drug conjugates (search).
"The innovation ecosystem and talent pool of the Zhongguancun Life Science Park (search) in Changping district have greatly supported our R&D efforts," said Xiaodong Wang, co-founder and chairman of the Scientific Advisory Board of BeOne.
Track Record of Innovation
The Changping center has already demonstrated its scientific capabilities through the discovery of zanubrutinib, a breakthrough oncology (search) treatment. "Zanubrutinib, discovered in our R&D Innovation Center in Changping, is a testament to how science transforms patients' lives," Wang noted.
The success of zanubrutinib validates the center's research approach and highlights its potential for future drug discoveries. Wang emphasized the facility's ongoing mission, stating, "Going forward, this center will remain a vital innovation engine powering scientific breakthroughs for patients worldwide."
Global Pipeline and Research Network
BeOne's global R&D network spans multiple countries and regions, with over 40 products in clinical or commercial stages. The company has maintained significant momentum in drug development, advancing 13 new molecular entities in 2024 alone. The expanded Changping center is set to reinforce BeOne's leadership in oncology (search) research and contribute to this robust pipeline.
The facility's focus on advanced therapeutic platforms, including targeted protein degradation (search) and antibody-drug conjugates (search), positions BeOne at the forefront of next-generation cancer treatment development. These cutting-edge approaches represent some of the most promising areas in modern oncology (search) research.